Phuc Tuong Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Phuc Tuong Pham has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Thanh Luan Nguyen
Nam Can Tho University
5 shared publications - Hoang Ngoc Thao Duong
Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho City, Vietnam
4 shared publications - Van Hoang Nam Ho
Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho, Vietnam
4 shared publications - Van Phieu Duong
Nam Can Tho University
4 shared publications - Cong Dang Tran
Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho, Vietnam
3 shared publications - Quang Dai Le
Faculty of Medicine, College of Health Sciences, Nam Can Tho University, Can Tho, Vietnam
3 shared publications
Latest Publications
- 11 May 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Early Magnesium Sulfate Administration and Mortality in Critically Ill Patients with Pneumonia: A Retrospective Analysis of the MIMIC-IV Database
Background: Disturbances in magnesium homeostasis and magnesium supplementation are common in critical illness; however, the association between early intravenous magnesium sulfate administration and clinical outcomes in critically ill patients with pneumonia remains unclear. Methods: This retrospective observational cohort study used data from the Medical Information Mart for Intensive Care IV (version 3.1) database and included critically ill patients admitted to the intensive care unit (ICU) with pneumonia. Patients were classified according to early exposure to intravenous magnesium sulfate, defined as administration from 6 h before to 24 h after ICU admission, or no exposure during this period. The primary outcome was 30-day all-cause mortality, with secondary outcomes including 60-day and 90-day mortality. Associations were evaluated using multivariable Cox proportional hazards models, with prespecified subgroup, interaction, and sensitivity analyses, including propensity score matching. Results: Among 9203 eligible patients, 2975 (32.3%) received early intravenous magnesium sulfate. Magnesium sulfate administration was associated with lower 30-day mortality after multivariable adjustment (adjusted hazard ratio [aHR] 0.84; 95% confidence interval [CI] 0.76-0.94; p = .002). Similar associations were observed for 60-day mortality (aHR 0.86; 95% CI 0.78-0.95; p = .002) and 90-day mortality (aHR 0.87; 95% CI 0.80-0.96; p = .004). Subgroup analysis identified a significant interaction for sepsis status (p for interaction = .007). In a propensity score–matched cohort, magnesium sulfate administration remained associated with lower 30-day mortality (aHR 0.85; 95% CI 0.74-0.96; p = .012). Conclusions: In critically ill patients with pneumonia, early intravenous magnesium sulfate administration was associated with lower mortality. These findings are hypothesis-generating and suggest the need for prospective studies to clarify causality and define optimal dosing and duration of magnesium supplementation in this population.
- 11 May 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Early Magnesium Sulfate Administration and Mortality in Critically Ill Patients with Pneumonia: A Retrospective Analysis of the MIMIC-IV Database
Background: Disturbances in magnesium homeostasis and magnesium supplementation are common in critical illness; however, the association between early intravenous magnesium sulfate administration and clinical outcomes in critically ill patients with pneumonia remains unclear. Methods: This retrospective observational cohort study used data from the Medical Information Mart for Intensive Care IV (version 3.1) database and included critically ill patients admitted to the intensive care unit (ICU) with pneumonia. Patients were classified according to early exposure to intravenous magnesium sulfate, defined as administration from 6 h before to 24 h after ICU admission, or no exposure during this period. The primary outcome was 30-day all-cause mortality, with secondary outcomes including 60-day and 90-day mortality. Associations were evaluated using multivariable Cox proportional hazards models, with prespecified subgroup, interaction, and sensitivity analyses, including propensity score matching. Results: Among 9203 eligible patients, 2975 (32.3%) received early intravenous magnesium sulfate. Magnesium sulfate administration was associated with lower 30-day mortality after multivariable adjustment (adjusted hazard ratio [aHR] 0.84; 95% confidence interval [CI] 0.76-0.94; p = .002). Similar associations were observed for 60-day mortality (aHR 0.86; 95% CI 0.78-0.95; p = .002) and 90-day mortality (aHR 0.87; 95% CI 0.80-0.96; p = .004). Subgroup analysis identified a significant interaction for sepsis status (p for interaction = .007). In a propensity score–matched cohort, magnesium sulfate administration remained associated with lower 30-day mortality (aHR 0.85; 95% CI 0.74-0.96; p = .012). Conclusions: In critically ill patients with pneumonia, early intravenous magnesium sulfate administration was associated with lower mortality. These findings are hypothesis-generating and suggest the need for prospective studies to clarify causality and define optimal dosing and duration of magnesium supplementation in this population.
- Open Access
- 27 March 2026
- Published by Wolters Kluwer Health in Emergency and Critical Care Medicine
- Vol. 6 (1) , 3-5
Hypomagnesemia: the 12th pitfall in interpreting hyperlactatemia in sepsis
- 27 March 2026
- Published by Wolters Kluwer Health in Emergency and Critical Care Medicine
- Vol. 6 (1) , 3-5
Open AccessHypomagnesemia: the 12th pitfall in interpreting hyperlactatemia in sepsis
- Open Access
- 10 November 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-3
Rethinking hypomagnesemia: diagnostic thresholds and metabolic implications in critical illness
- 10 November 2025
- Published by Springer Nature in Critical Care
- Vol. 29 (1) , 1-3
Open AccessRethinking hypomagnesemia: diagnostic thresholds and metabolic implications in critical illness
- Open Access
- 5 October 2025
- Published by Springer Nature in Pneumonia
- Vol. 17 (1) , 1-5
Corticosteroids in non-viral acute respiratory distress syndrome (ARDS): recommendations outpace evidence – a concise review
The 2024 global redefinition of acute respiratory distress syndrome (ARDS) broadens diagnostic criteria to include patients on non-invasive respiratory support. While this inclusivity enhances early recognition, it also introduces heterogeneity in disease severity, inflammatory burden, and treatment responsiveness–complicating the use of corticosteroids. Although recent guidelines recommend corticosteroids for moderate-to-severe ARDS, they fall short of specifying optimal timing, dosing, and patient selection. The DEXA-ARDS trial showed that high-dose dexamethasone reduced mortality in moderate-to-severe ARDS regardless of etiology, but its generalizability to less severe or non-intubated patients remains unclear. Conversely, in severe community-acquired pneumonia (CAP), hydrocortisone regimens used in CAPE-COD and APROCCHSS trials demonstrated mortality benefits, suggesting a particular therapeutic niche for corticosteroids in non-viral, infection-associated ARDS. A recent network meta-analysis suggests that low-dose methylprednisolone may reduce ARDS mortality, though phenotype-specific efficacy is not well defined. Despite these encouraging signals, key questions persist: Which corticosteroid? At what dose? For which ARDS phenotype? As evidence accumulates unevenly across ARDS subtypes, guideline-endorsed recommendations may inadvertently mask the nuances required for individualized therapy. Until precision approaches are better defined, clinicians must balance empirical benefit with thoughtful restraint in applying corticosteroids to non-viral ARDS. This concise review summarizes current evidence, key limitations, and pragmatic phenotype-informed strategies for corticosteroid use in non-viral ARDS.
- 5 October 2025
- Published by Springer Nature in Pneumonia
- Vol. 17 (1) , 1-5
Open AccessCorticosteroids in non-viral acute respiratory distress syndrome (ARDS): recommendations outpace evidence – a concise review
The 2024 global redefinition of acute respiratory distress syndrome (ARDS) broadens diagnostic criteria to include patients on non-invasive respiratory support. While this inclusivity enhances early recognition, it also introduces heterogeneity in disease severity, inflammatory burden, and treatment responsiveness–complicating the use of corticosteroids. Although recent guidelines recommend corticosteroids for moderate-to-severe ARDS, they fall short of specifying optimal timing, dosing, and patient selection. The DEXA-ARDS trial showed that high-dose dexamethasone reduced mortality in moderate-to-severe ARDS regardless of etiology, but its generalizability to less severe or non-intubated patients remains unclear. Conversely, in severe community-acquired pneumonia (CAP), hydrocortisone regimens used in CAPE-COD and APROCCHSS trials demonstrated mortality benefits, suggesting a particular therapeutic niche for corticosteroids in non-viral, infection-associated ARDS. A recent network meta-analysis suggests that low-dose methylprednisolone may reduce ARDS mortality, though phenotype-specific efficacy is not well defined. Despite these encouraging signals, key questions persist: Which corticosteroid? At what dose? For which ARDS phenotype? As evidence accumulates unevenly across ARDS subtypes, guideline-endorsed recommendations may inadvertently mask the nuances required for individualized therapy. Until precision approaches are better defined, clinicians must balance empirical benefit with thoughtful restraint in applying corticosteroids to non-viral ARDS. This concise review summarizes current evidence, key limitations, and pragmatic phenotype-informed strategies for corticosteroid use in non-viral ARDS.